Erratum: Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV (Supportive Care in Cancer (DOI 10.1007/s00520-012-1667-5));Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV

Supportive Care in Cancer

Volumn 21, Issue 5, 2013, Pages 1313-1319

  Vincenzi, Bruno ^a   Frezza, Anna Maria ^a   Schiavon, Gaia ^b   Spoto, Chiara ^a   Addeo, Raffaele ^c   Catalano, Vincenzo ^d   Graziano, Francesco ^e   Santini, Daniele ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Ospedale San Giovanni di Dio   (Italy)

^d AO Ospedali Riuniti Marche Nord   (Italy)

^e UNIVERSITY OF URBINO   (Italy)

Author keywords

Clinical predictive factors; Colorectal cancer; Neurotoxicity; Oxaliplatin induced neuropathy

Indexed keywords

ALBUMIN; CALCIUM; CYANOCOBALAMIN; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; MAGNESIUM; OXALIPLATIN;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; COLORECTAL CANCER; COLORECTAL SURGERY; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLIC ACID DEFICIENCY; HIGH RISK POPULATION; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84879690588     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1724-8     Document Type: Erratum

References (15)

1. André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. N Engl J Med 350:2343-2351
2. Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471
3. Attal N, Bouhassira D, Gautron M et al (2009) Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 144:245-252
4. Won HH, Lee J, Park JO et al (2012) Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118(11):2828-2836
5. Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006
6. Engelen W, Bouten A, De Leeuw I, De Block C (2000) Are low magnesium levels in type 1 diabetes associated with electromyographical signs of polyneuropathy? Magnes Res 13:197-203
7. De Leeuw I, Engelen W, De Block C, Van Gaal L (2004) Long-term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes Res 17:109-114
8. Grothey A, Nikcevich DA, Sloan JA et al (2011) Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29:421-427
9. Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusion: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061
10. Grothey A, Hart LL, Rowland KM et al (2008) Intermittent oxaliplatin administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 26:2008
11. Ferrari LF, Levine JD (2010) Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms. Eur J Neurosci 32:811-818
12. Ramanathan RK, Rothenberg ML, de Gramont A (2010) Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 21:754-758
13. Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091
14. Yang YH, Lin JK, Chen WS et al (2012) Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer 20(7):1491-1497
15. Durand JP, Deplanque G, Montheil V et al (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200-205